JP6030114B2 - 放射線照射または化学物質による傷害を治療するための方法 - Google Patents

放射線照射または化学物質による傷害を治療するための方法 Download PDF

Info

Publication number
JP6030114B2
JP6030114B2 JP2014500487A JP2014500487A JP6030114B2 JP 6030114 B2 JP6030114 B2 JP 6030114B2 JP 2014500487 A JP2014500487 A JP 2014500487A JP 2014500487 A JP2014500487 A JP 2014500487A JP 6030114 B2 JP6030114 B2 JP 6030114B2
Authority
JP
Japan
Prior art keywords
cells
adherent stromal
stromal cells
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014500487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508799A (ja
JP2014508799A5 (enExample
Inventor
ザミ アバーマン，
ザミ アバーマン，
ラファエル ゴロデツキー，
ラファエル ゴロデツキー，
Original Assignee
プルリステム リミテッド
プルリステム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/069,130 external-priority patent/US20110171182A1/en
Priority claimed from US13/161,334 external-priority patent/US20110293583A1/en
Application filed by プルリステム リミテッド, プルリステム リミテッド filed Critical プルリステム リミテッド
Publication of JP2014508799A publication Critical patent/JP2014508799A/ja
Publication of JP2014508799A5 publication Critical patent/JP2014508799A5/ja
Application granted granted Critical
Publication of JP6030114B2 publication Critical patent/JP6030114B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
JP2014500487A 2011-03-22 2012-03-22 放射線照射または化学物質による傷害を治療するための方法 Active JP6030114B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US13/069,130 2011-03-22
US13/069,130 US20110171182A1 (en) 2006-03-23 2011-03-22 Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US201161497400P 2011-06-15 2011-06-15
US61/497,400 2011-06-15
US13/161,334 US20110293583A1 (en) 2006-03-23 2011-06-15 Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US13/161,334 2011-06-15
US201261595485P 2012-02-06 2012-02-06
US61/595,485 2012-02-06
PCT/IB2012/000664 WO2012127320A1 (en) 2011-03-22 2012-03-22 Methods for treating radiation or chemical injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016205482A Division JP6266726B2 (ja) 2011-03-22 2016-10-19 放射線照射または化学物質による傷害を治療するための方法

Publications (3)

Publication Number Publication Date
JP2014508799A JP2014508799A (ja) 2014-04-10
JP2014508799A5 JP2014508799A5 (enExample) 2015-11-26
JP6030114B2 true JP6030114B2 (ja) 2016-11-24

Family

ID=45976430

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014500487A Active JP6030114B2 (ja) 2011-03-22 2012-03-22 放射線照射または化学物質による傷害を治療するための方法
JP2016205482A Active JP6266726B2 (ja) 2011-03-22 2016-10-19 放射線照射または化学物質による傷害を治療するための方法
JP2017244534A Active JP6548714B2 (ja) 2011-03-22 2017-12-20 放射線照射または化学物質による傷害を治療するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016205482A Active JP6266726B2 (ja) 2011-03-22 2016-10-19 放射線照射または化学物質による傷害を治療するための方法
JP2017244534A Active JP6548714B2 (ja) 2011-03-22 2017-12-20 放射線照射または化学物質による傷害を治療するための方法

Country Status (7)

Country Link
US (2) US10722541B2 (enExample)
EP (2) EP2689008B1 (enExample)
JP (3) JP6030114B2 (enExample)
KR (2) KR101903339B1 (enExample)
HK (1) HK1244502A1 (enExample)
IL (3) IL228470A (enExample)
WO (1) WO2012127320A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061472A (ja) * 2011-03-22 2017-03-30 プルリステム リミテッド 放射線照射または化学物質による傷害を治療するための方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101490449B1 (ko) * 2006-03-23 2015-02-05 플루리스템 리미티드 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP2731440A4 (en) * 2011-07-15 2015-04-29 Anthrogenesis Corp RADIATION LESSON TREATMENT USING ADHESENT CELLS DERIVED FROM AMNIOS
JP2015521630A (ja) * 2012-06-26 2015-07-30 ラスティー プロパティー ホールディングス プロプライエタリー リミテッド 頭痛の頻度および／または重症度を下げるための組成物および方法
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
CN107864627A (zh) * 2015-03-23 2018-03-30 普拉里斯坦有限公司 包含粘附基质细胞的方法和组合物
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CA3125311A1 (en) * 2019-03-27 2020-10-01 Pluristem Ltd. Methods and compositions for aesthetic and cosmetic treatment and stimulating hair growth
EP4164706A1 (en) 2019-12-04 2023-04-19 Centre Hospitalier Universitaire Vaudois (CHUV) Device and process for tissue-engineering and regenerative medicine
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
US20230293598A1 (en) * 2022-03-15 2023-09-21 Narkeshyo LLC Prevention of radiation exposure associated pathology by treatment with umbilical cord derived regenerative cells
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5266476A (en) 1985-06-18 1993-11-30 Yeda Research & Development Co., Ltd. Fibrous matrix for in vitro cell cultivation
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5629186A (en) 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
CA2237890C (en) 1995-11-16 2011-03-29 Case Western Reserve University In vitro chondrogenic induction of human mesenchymal stem cells
US6291240B1 (en) 1998-01-29 2001-09-18 Advanced Tissue Sciences, Inc. Cells or tissues with increased protein factors and methods of making and using same
DE69922933T2 (de) 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
EP1064353B1 (en) 1998-03-18 2002-11-06 Massachusetts Institute Of Technology Vascularized perfused microtissue/micro-organ arrays
CA2348770A1 (en) 1998-10-26 2000-05-04 Philadelphia Health & Education Corporation Stromal cell use
US6153432A (en) 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
MXPA01007820A (es) 1999-02-04 2003-06-19 Technion Res & Dev Foundation Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras.
RU2306335C2 (ru) 1999-03-10 2007-09-20 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Стволовые клетки и решетки, полученные из жировой ткани
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US20030161817A1 (en) 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1261694B1 (en) 2000-02-26 2008-01-16 Artecel, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
ATE360063T1 (de) 2000-10-12 2007-05-15 Agency Science Tech & Res Nicht störendes, dreidimensionales system für die kultivierung und ernte verankerungsabhängiger zellen
US20020045260A1 (en) 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
WO2002040639A2 (en) 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
MXPA03005014A (es) 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
EP2338983B1 (en) 2001-02-14 2015-10-07 Anthrogenesis Corporation Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7504099B2 (en) 2001-12-27 2009-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of inducing or enhancing connective tissue repair
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
AU2003220424A1 (en) 2002-03-19 2003-10-08 Advanced Research And Technology Transfer Adipose stromal stem cells for tissue and vascular modification
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2483010A1 (en) 2002-04-19 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Placental derived stem cells and uses thereof
US6875605B1 (en) 2002-08-21 2005-04-05 Florida State University Research Foundation, Inc. Modular cell culture bioreactor and associated methods
US20040258670A1 (en) 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
WO2004076642A2 (en) 2003-02-27 2004-09-10 The Rockefeller University Method for modulating epithelial stem cell lineage
ES2569780T3 (es) 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
WO2005113751A1 (en) 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
DE102004043256B4 (de) 2004-09-07 2013-09-19 Rheinische Friedrich-Wilhelms-Universität Bonn Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension
WO2006138552A2 (en) 2005-06-15 2006-12-28 Government Of The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Tissue engineered cartilage, method of making same, therapeutic and cosmetic surgical applications using same
KR20180105266A (ko) 2005-12-29 2018-09-27 안트로제네시스 코포레이션 태반 줄기 세포 집단
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20080286249A1 (en) * 2006-01-12 2008-11-20 Varney Timothy R Use of mesenchymal stem cells for treating genetic diseases and disorders
US20110171182A1 (en) 2006-03-23 2011-07-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110293583A1 (en) 2006-03-23 2011-12-01 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
KR101490449B1 (ko) 2006-03-23 2015-02-05 플루리스템 리미티드 세포 증식 방법 및 세포의 용도 및 치료를 위해 그 세포에 의해 제조되는 조절된 배지
US20180008649A1 (en) 2006-03-23 2018-01-11 Pluristem Ltd. Adherent stromal cells derived from placentas of multiple donors and uses thereof
WO2011132087A1 (en) * 2010-04-23 2011-10-27 Pluristem Ltd. Adherent stromal cells derived from plancentas of multiple donors and uses thereof
EP1845154A1 (en) * 2006-04-12 2007-10-17 RNL Bio Co., Ltd. Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same
CN103356710A (zh) 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
ES2392729T5 (es) 2007-09-19 2015-08-28 Pluristem Ltd. Células adherentes de tejidos adiposos o de placenta y uso de las mismas en terapia
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
EP2303293A1 (en) 2008-05-27 2011-04-06 Pluristem Ltd. Methods of treating inflammatory colon diseases
WO2010033285A2 (en) 2008-06-26 2010-03-25 Spectrum Health Method for treating and preventing radiation damage using genetically modified mesenchymal stem cells
US9096827B2 (en) 2008-09-02 2015-08-04 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
CA2735790C (en) 2008-09-02 2017-02-28 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
EP2331957B1 (en) 2008-09-02 2016-11-02 Pluristem Ltd. Methods of selection of cells for transplantation
EP2375907B1 (en) * 2008-11-21 2019-02-27 Celularity, Inc. Treatment of diseases, disorders or conditions of the lung using placental cells
US9175262B2 (en) 2009-11-30 2015-11-03 Pluristerm Ltd. Adherent cells from placenta and use of same in disease treatment
WO2011147967A1 (en) 2010-05-27 2011-12-01 Georg Duda Skeletal muscle regeneration using mesenchymal stem cells
KR101903339B1 (ko) * 2011-03-22 2018-10-01 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법
KR101910685B1 (ko) 2011-04-15 2018-10-22 플루리스템 리미티드 세포 수집 방법 및 시스템
AU2013311289B2 (en) 2012-09-04 2017-11-16 Pluristem Ltd. Methods for prevention and treatment of preeclampsia
US9512393B2 (en) 2012-09-06 2016-12-06 Pluristem Ltd. Devices and methods for culture of cells
KR102074024B1 (ko) 2012-10-31 2020-02-05 플루리스템 리미티드 생물학적 물질을 해동하기 위한 방법 및 장치

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061472A (ja) * 2011-03-22 2017-03-30 プルリステム リミテッド 放射線照射または化学物質による傷害を治療するための方法
JP2018070646A (ja) * 2011-03-22 2018-05-10 プルリステム リミテッド 放射線照射または化学物質による傷害を治療するための方法

Also Published As

Publication number Publication date
IL228470A (en) 2017-10-31
JP2014508799A (ja) 2014-04-10
EP3260533A1 (en) 2017-12-27
KR20180027610A (ko) 2018-03-14
WO2012127320A1 (en) 2012-09-27
JP6548714B2 (ja) 2019-07-24
HK1244502A1 (en) 2018-08-10
KR101835917B1 (ko) 2018-03-07
IL267417B (en) 2020-04-30
JP6266726B2 (ja) 2018-01-24
US20170368106A1 (en) 2017-12-28
IL228470A0 (en) 2013-12-31
EP3260533B1 (en) 2019-09-11
JP2018070646A (ja) 2018-05-10
IL254694A0 (en) 2017-11-30
IL254694B (en) 2019-07-31
EP2689008A1 (en) 2014-01-29
IL267417A (en) 2019-09-01
JP2017061472A (ja) 2017-03-30
KR20140020290A (ko) 2014-02-18
KR101903339B1 (ko) 2018-10-01
US20200306319A1 (en) 2020-10-01
US10722541B2 (en) 2020-07-28
EP2689008B1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
JP6266726B2 (ja) 放射線照射または化学物質による傷害を治療するための方法
US20140017209A1 (en) Methods for treating radiation or chemical injury
EP2626417B1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110293583A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110171182A1 (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1188812B (en) Methods for treating radiation or chemical injury
HK1188812A (en) Methods for treating radiation or chemical injury
WO2020095230A1 (en) Therapeutic methods and compositions
HK1187950B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
HK1177759B (en) Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150217

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150402

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160920

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161019

R150 Certificate of patent or registration of utility model

Ref document number: 6030114

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250